⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 1, 2024JGH OpenOpen Access

MELD3.0 is superior to MELDNa and MELD for prediction of mortality in patients with cirrhosis: An external validation in a multi‐ethnic population

Hong‐Yi Lin Pooi Ling Loi Jeanette Ng Liang Shen Wei‐Quan Teo Amber Chung Prema Raj Pik‐Eu Chang

View Full Paper

Ask AI

Bookmark

Share

Abstract

The model for end-stage liver disease (MELD) was updated to MELDNa and recently to MELD3.0 to predict survival of cirrhotic patients. We validated the prognostic performance of MELD3.0 and compared with MELDNa and MELD amongst cirrhotic inpatients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lin et al. (2024) studied this question.

synapsesocial.com/papers/68e66b13b6db6435875f6176 https://doi.org/10.1002/jgh3.13098

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort2024 · 8 citations
2Comparison of MELD, MELD-Na, and MELD 3.0 scoring systems for transplant prioritization in the turkish population: A multicenter studyOriginal Research · 2026 · 2 citations
3Performances and Validation of MELD 3.0 and ReMELD-Na Scoring Systems: A German Clinical Cohort Study2025
4Validation of MELD 3.0 and ReMELD-Na scoring systems: a German clinical cohort study2025
5Comparison of Postoperative MELD‐Based Scores in Predicting Mortality After Liver Transplantation: A Retrospective Comparative StudyCohort Study · 2026